Biocryst Pharmaceuticals (BCRX) Capital Expenditures Growth (3y) (2013 - 2026)
Biocryst Pharmaceuticals (BCRX) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 6.52% |
| 3 | Zoetis | 32.71 Bn | 30.77 Bn | 1.62 Bn | 232.22% |
| 4 | Takeda Pharmaceutical | 27.62 Bn | 23.56 Bn | 4.39 Bn | 1.64% |
| 5 | United Therapeutics | 23.18 Bn | 21.03 Bn | 648.10 Mn | 75.58% |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn | -5.84% |
| 8 | Neurocrine Biosciences | 17.80 Bn | 16.48 Bn | 800.70 Mn | 32.64% |
| 9 | Elanco Animal Health | 12.67 Bn | 12.24 Bn | 785.00 Mn | 28.56% |
| 10 | Biocryst Pharmaceuticals | 2.35 Bn | 2.29 Bn | 151.04 Mn | 56.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.05% |
| Dec 31, 2025 | -58.89% |
| Sep 30, 2025 | 50.54% |
| Jun 30, 2025 | 63.63% |
| Dec 31, 2024 | -33.98% |
| Sep 30, 2024 | 7.15% |
| Jun 30, 2024 | -31.79% |
| Mar 31, 2024 | 33.40% |
| Dec 31, 2023 | -131.54% |
| Sep 30, 2023 | 79.03% |
| Jun 30, 2023 | 87.36% |
| Mar 31, 2023 | 11.32% |
| Dec 31, 2022 | 87.34% |
| Sep 30, 2022 | 28.23% |
| Jun 30, 2022 | 41.02% |
| Mar 31, 2022 | 63.44% |
| Dec 31, 2021 | 120.04% |
| Sep 30, 2021 | 107.25% |
| Jun 30, 2021 | 63.50% |
| Mar 31, 2021 | 41.42% |